Dermapharm expands COVID-19 vaccine production capacity at ex-Merck site
The company's additional production capacities are scheduled to go into operation in May 2021
CDMO Dermapharm, a manufacturer of the Pfizer/BioNTech COVID-19 vaccine Comirnaty (formerly known as BNT162b2), says it is expanding capacity at its Reinbek, Germany site due to high demand for the shot.
Additional production capacities are now being established at Allergopharma GmbH & Co. KG, a subsidiary of Dermapharm, at Reinbek, which was formerly Merck KGaA's European allergy business before the pharma firm divested it in March 2020.
Dermapharm has said it is already begun to recruit personnel and train employees at its main production site in Brehna near Leipzig in readiness to start vaccine production as soon as possible.The additional production capacities are scheduled to go into operation in May 2021.
According to Dr Hans-Georg Feldmeier, Chairman of the Management Board of Dermapharm Holding SE, the capacities in Reinbek will "significantly exceed" its production capacities in Brehna.
Dermapharm signed a cooperation and supply agreement with BioNTech SE last September, and expanded production and special storage capacities for the formulation, as well as the aseptic filling, packaging (fill & finish) and storage of the vaccine at its mibe GmbH Arzneimittelsite site in Brehna, Germany.
The vaccine has been produced in Brehna since the beginning of October 2020.
Dermapharm said it expects the BioNTech partnership to contribute a "high double-digit million € amount" to its consolidated sales in the full year 2021.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance